Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKinsey
Johnson and Johnson
Harvard Business School
Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Teva Parenteral Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for TEVA PARENTERAL, and what generic and branded alternatives to TEVA PARENTERAL drugs are available?

TEVA PARENTERAL has forty-seven approved drugs.

There are six tentative approvals on TEVA PARENTERAL drugs.

Summary for Teva Parenteral
US Patents:0
Tradenames:39
Ingredients:37
NDAs:47
Patent Litigation for Teva Parenteral: See patent lawsuits for Teva Parenteral

Drugs and US Patents for Teva Parenteral

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Parenteral GENTAMICIN SULFATE gentamicin sulfate INJECTABLE;INJECTION 063106-002 Nov 21, 1991 DISCN No No   Start Trial   Start Trial
Teva Parenteral CYTARABINE cytarabine INJECTABLE;INJECTION 016793-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial
Teva Parenteral DEXAMETHASONE SODIUM PHOSPHATE dexamethasone sodium phosphate INJECTABLE;INJECTION 081125-001 Aug 31, 1990 DISCN No No   Start Trial   Start Trial
Teva Parenteral AMPHOTERICIN B amphotericin b INJECTABLE;INJECTION 064062-001 Mar 31, 1995 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Parenteral

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Parenteral CYTARABINE cytarabine INJECTABLE;INJECTION 016793-001 Approved Prior to Jan 1, 1982 3,444,294   Start Trial
Teva Parenteral CYTARABINE cytarabine INJECTABLE;INJECTION 016793-002 Approved Prior to Jan 1, 1982 3,444,294   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Moodys
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.